Related Experiment Video
Updated: Jul 11, 2026
07:20
Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy
Published on: August 9, 2024
[Guide to the comprehensive treatment of spasticity]
F Vivancos-Matellano1, S I Pascual-Pascual, J Nardi-Vilardaga
1Servicio de Neurología, Hospital Universitario La Paz, 28046 Madrid, Espana. franvivancos@wanadoo.es
Revista De Neurologia
|September 28, 2007
Summary
Spasticity, a condition affecting both children and adults, presents significant challenges impacting movement and quality of life. Early, individualized, and multidisciplinary treatment is crucial for managing spasticity and its complications.
Area of Science:
- Neurology
- Rehabilitation Medicine
- Orthopedics
Context:
- Spasticity is a prevalent neurological disorder affecting individuals across all age groups.
- It is a key component of the upper motor neuron syndrome, leading to diverse functional impairments.
- Associated complications include joint stiffness, pain, and difficulties with daily activities.
Purpose:
- To provide a comprehensive understanding of spasticity, encompassing its causes, epidemiology, and natural progression.
- To outline a rational and integrated therapeutic approach, considering pharmacological, rehabilitative, and surgical interventions.
- To emphasize the importance of individualized treatment plans and realistic goal setting.
Summary:
- Spasticity, characterized by increased muscle tone and involuntary contractions, arises from various neurological conditions like cerebral palsy, stroke, and spinal cord injury.
- The condition progresses to chronic stages, involving soft tissue alterations that exacerbate functional limitations.
- Current management strategies encompass medication, physical therapy, orthotics, and surgical options.
Impact:
- Effective spasticity management requires a collaborative, multidisciplinary team approach involving various medical specialists.
- Early intervention is vital to mitigate severe, long-term complications associated with spasticity.
- Optimizing patient outcomes necessitates personalized treatment strategies tailored to individual needs and agreed-upon goals.
Related Concept Videos
01:29Spasmolytic Agents: Chemical Classification
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...